SCHEMBL483978

SCHEMBL483978

CC(F)OCCOCCOc1ccc2nc(-c3ccc(N(C)C)cc3)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.52
MAPT P10636 8/20 0.50
NCF1 P14598 4/20 0.45
MAOB P27338 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483977 0.87 APP (0.65) APPMAPTNCF1
SCHEMBL12403454 0.85 APP (0.54) APPMAPTNCF1MAOB
SCHEMBL483770 0.84 APP (0.53) APPMAPTNCF1MAOB
SCHEMBL21974441 0.82 APP (0.50) APPMAPTNCF1MAOB
SCHEMBL18065066 0.80 APP (0.58) APPMAPTNCF1MAOB
SCHEMBL22907228 0.79 APP (0.49) APPMAPTNCF1MAOB
SCHEMBL3722782 0.78 MAPT (0.39) APPMAPTNCF1MAOB
SCHEMBL19101883 0.78 MAPT (0.61) APPMAPTMAOB
SCHEMBL20129292 0.77 APP (0.47) APPMAPTNCF1MAOB
SCHEMBL18027563 0.77 MAPT (0.47) APPMAPTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-8491869-B2 Imaging agents for detecting neurological disorders ELI LILLY AND COMPANY (US) 2013-07-23 US disclosed
EP-2411057-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2012-02-01 EP disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 APP 2/4885MAPT 1/4885NCF1 2099/4885
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 APP 2/4885MAPT 1/4885NCF1 2683/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 APP 2/4885MAPT 1/4885NCF1 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.